Inhibition of both MAO-A and MAO-B required for the production of hypermotility in mice with the 5HT uptake inhibitors chlorimipramine and femoxetine.
D000818:Animals; D000840:Anisoles / Q000494:pharmacology*; D002997:Clomipramine / Q000494:pharmacology*; D003010:Clorgyline / Q000494:pharmacology; D003984:Dibenzazepines / Q000494:pharmacology*; D004347:Drug Interactions; D005260:Female; D006801:Humans; D006948:Hyperkinesis / Q000139:chemically induced; D051379:Mice; D008996:Monoamine Oxidase Inhibitors / Q000494:pharmacology*; D009043:Motor Activity / Q000187:drug effects*; D010627:Phenethylamines / Q000494:pharmacology*; D010880:Piperidines / Q000494:pharmacology*; D013268:Stimulation, Chemical
D000840:Anisoles; D003984:Dibenzazepines; D008996:Monoamine Oxidase Inhibitors; D010627:Phenethylamines; D010880:Piperidines; C010655:femoxetine; D003010:Clorgyline; D002997:Clomipramine